


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**BEST AVAILABLE COPY**

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

Application Number	09/991,627
Filing Date	11/23/2001
First Named Inventor	George Jackowski
Art Unit	1643
Examiner Name	
Attorney Docket Number	2132.106

RECEIVED
OCT 02 2003
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		M. VALLE et al, "APO-AI Decrease and Triglycerides Increase Serum Levels in Hyperinsulinemic Obese Children", Clinical Chemistry and Laboratory Medicine, 39:S247 XP009008523 (May 2001) (Abstract)	
		K. MURAO et al, "Effects of Glucose and Insulin on Rat Apolipoprotein A-I Gene Expression", J. Biol. Chem., 273(30):18959-18965 (July, 1998)	
		K. MOSKOWITZ et al, "Fibrinogen Coating Density Affects the Conformation of Immobilized Fibrinogen: Implications for Platelet Adhesion and Spreading", Thrombosis and Haemostasis, 79(4):824-831 (April, 1998)	
		P. GRANT, "Polymorphisms of Coagulation/Fibrinolysis Genes: Gene Environment Interactions and Vascular Risk", Prostaglandins Leukotrienes and Essential Fatty Acids, 57(4-5):473-477 (October, 1997)	
		G. IMPERATORE et al, "Plasma Fibrinogen: A New Factor of the Metabolic Syndrome", Diabetes Care, 21(4):649-654 (April, 1998)	

Examiner Signature		Date Considered	2/5/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.